Sunmi Kim, Sungeun Kang, Gowoon Lee, Saeram Lee, Areum Jo, Kyunghee Kwak, Dohyung Kim, Dohyun Koh, Young Lim Kho, Sungkyoon Kim, Kyungho Choi
Urinary phthalate metabolites among elementary school children of Korea: sources, risks, and their association with oxidative stress marker
The Science of the total environment
tumorassociated antigens derived peptides constitute opportunity design offtheshelf mainline adjuvant anticancer immunotherapies broad array patients performant rational antigen selection pipeline would lay foundation immunotherapy trials potential enhance treatment tremendously benefiting patients suffering rare understudied cancers present experimentally validated datadriven computational pipeline selects ranks antigens multipronged approach addition minimizing risk immunerelated adverse events selecting antigens based expression profile tumor biopsies healthy tissues incorporated network analysisderived antigen indispensability index based computational modeling results candidate immunogenicity predictions machine learning ensemble model relying peptide physicochemical characteristics model study uveal melanoma human leukocyte antigen hla docking simulations experimental quantification peptidemajor histocompatibility complex binding affinities confirmed approach discriminates highbinding lowbinding affinity peptides performance similar established methodologies blinded validation experiments autologous tcells yielded peptide stimulationinduced interferon secretion cytotoxic activity despite high interdonor variability dissecting score contribution tested antigens revealed peptides potential induce cytotoxicity unsuitable due potential tissue damage instability expression properly discarded computational pipeline study demonstrate feasibility de novo computational selection antigens capacity induce antitumor immune response predicted low risk tissue damage translation clinic pipeline supports fast turnaround validation example adoptive tcell transfer preparations generalized personalized antigendirected immunotherapy settings